JAMA Author Interviews cover image

JAMA Author Interviews

Risankizumab for Ulcerative Colitis

Jul 22, 2024
Guest Gilaad G. Kaplan discusses Risankizumab for ulcerative colitis with JAMA Editor. Topics include personalized therapy with monoclonal antibodies targeting IL-23 pathway, phase 3 trial results showing higher remission rates, complexities in comparing risankizumab to placebo, and the importance of precision medicine in treatment strategies.
15:49

Podcast summary created with Snipd AI

Quick takeaways

  • Ulcerative colitis treatment challenges demand precision medicine and biomarker-guided decisions for optimal outcomes.
  • Risankizumab showcases significant efficacy in inducing and maintaining remission in ulcerative colitis patients.

Deep dives

Challenges in Ulcerative Colitis Treatment

Treating ulcerative colitis remains a challenge despite the availability of various medications. Patients with moderate to severe disease face hospitalizations and potentially colectomy. The primary goals of treatment are to induce remission and then maintain it to prevent reactivation of inflammation. For mild disease, 5-aminosalicylates are commonly used, while more advanced therapies target the pathogenesis of ulcerative colitis for moderate to severe cases.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode